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Associations of Trauma Exposure and Posttraumatic Stress
Symptoms With Venous Thromboembolism Over 22 Years in Women
Jennifer A. Sumner, PhD; Laura D. Kubzansky, PhD; Christopher Kabrhel, MD; Andrea L. Roberts, PhD; Qixuan Chen, PhD;
Ashley Winning, ScD; Paola Gilsanz, ScD; Eric B. Rimm, ScD; Maria M. Glymour, ScD; Karestan C. Koenen, PhD
Background-—Trauma exposure and posttraumatic stress disorder (PTSD) have been linked to myocardial infarction and stroke in
women, with biological and behavioral mechanisms implicated in underlying risk. The third most common cardiovascular illness,
venous thromboembolism (VTE), is a specific health risk for women. Given previous associations with other cardiovascular
diseases, we hypothesized that high levels of trauma and PTSD symptoms would be associated with higher risk of incident VTE in
younger and middle-aged women.
Methods and Results-—We used proportional hazards models to estimate hazard ratios (HRs) and 95% CIs for new-onset VTE (960
events) over 22 years in 49 296 women in the Nurses’ Health Study II. Compared to no trauma exposure, both trauma exposure
and PTSD symptoms were significantly associated with increased risk of developing VTE, adjusting for demographics, family
history, and childhood adiposity. Women with the most PTSD symptoms exhibited the greatest risk elevation: trauma/6 to 7
symptoms: HR=2.42 (95% CI, 1.83–3.20); trauma/4 to 5 symptoms: HR=2.00 (95% CI, 1.55–2.59); trauma/1 to 3 symptoms:
HR=1.44 (95% CI, 1.12–1.84); trauma/no symptoms: HR=1.72 (95% CI, 1.43–2.08). Results were similar, although attenuated,
when adjusting for VTE-relevant medications, medical conditions, and health behaviors.
Conclusions-—Women with the highest PTSD symptom levels had nearly a 2-fold increased risk of VTE compared to women
without trauma exposure in fully adjusted models. Trauma exposure alone was also associated with elevated VTE risk. Trauma and
PTSD symptoms may be associated with a hypercoagulable state. Treatment providers should be aware that women with trauma
exposure and PTSD symptoms may be vulnerable to VTE. ( J Am Heart Assoc. 2016;5:e003197 doi: 10.1161/
JAHA.116.003197)
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V enous thromboembolism (VTE), encompassing deep veinthrombosis (DVT) and pulmonary embolism (PE), is the
third most common cause of cardiovascular death and the
leading preventable cause of hospital-based death.1,2
Although VTE has been identified as a major public health
concern for men and women,2 certain factors make it
particularly relevant to women’s health.3 Female-specific risk
factors for VTE related to reproductive hormone exposure (eg,
due to contraceptive therapy, pregnancy, and hormone
therapy [HT]) have been documented,3 and VTE is a leading
cause of mortality among pregnant and recently postpartum
women in the United States.2 Additionally, VTE incidence
rates are higher in women of childbearing age than in men of
the same age,4,5 likely reflecting VTE induced by pregnancy
and/or oral contraceptive use during childbearing years.
Given the disease burden and highly recurrent nature of VTE
—a largely preventable condition—greater insight into factors
that may increase risk or promote prevention, particularly in
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women, is a significant public health priority.2,3 Furthermore,
given that 26% to 47% of VTE cases are classified as occurring
in the absence of major established risk factors (eg, cancer,
surgery, and pregnancy),6 better understanding of VTE risk
has important clinical relevance.
VTE shares risk factors (eg, hypertension, obesity, cigarette
smoking) and pathophysiology (eg, inflammation, hypercoag-
ulability, endothelial damage) with atherothrombosis,7 the
primary cause of cardiovascular disease.8 Consequently, in
recent years, VTE has been conceptualized as part of a
pancardiovascular syndrome that includes coronary artery
disease, peripheral artery disease, and cerebrovascular
disease.7 Growing evidence suggests that psychosocial
factors, such as depression, which have been linked to
cardiovascular risk more broadly, are also associated with VTE
risk in particular.9,10 The majority of individuals in the general
population (at least 60% according to most studies11,12) are
exposed to 1 or more traumatic events (eg, sexual assault,
physical assault, combat, natural disasters) during their
lifetime. Posttraumatic stress disorder (PTSD) is a psycholog-
ical consequence of exposure to such traumatic events, and is
characterized by symptoms of re-experiencing of the trauma,
avoidance of trauma reminders, negative alterations in mood
and thinking, and hyperarousal. PTSD is twice as common in
women than in men; 1 in 10 women are estimated to
develop PTSD in their lifetime.11 PTSD has been increasingly
identified as a cardiovascular risk factor,13 with effects
particularly striking in women.14 Furthermore, PTSD has been
linked to pathophysiological processes implicated in VTE,
including inflammation,15 hypercoagulability,16 and endothe-
lial damage.17 One study suggested that PE incidence was
higher after compared with before exposure to a natural
disaster, a type of traumatic event commonly associated with
psychological distress.18 However, research examining a
range of traumatic events commonly associated with psycho-
logical distress, PTSD, and risk for developing VTE among
initially healthy individuals is lacking.
In this study, we investigated associations of trauma
exposure and PTSD symptoms with risk of incident VTE over a
22-year period using data from the Nurses’ Health Study II
(NHS II), an ongoing cohort study of younger and middle-aged
women. Whereas research on PTSD and risk for chronic
disease often conflates trauma exposure and PTSD symp-
toms, we were able to examine the effects of trauma and
PTSD symptoms separately. Consistent with prior findings
related to trauma exposure, PTSD symptoms, and incident
myocardial infarction (MI) and stroke in this sample,14 we
hypothesized that, compared to no trauma exposure, trauma
exposure and PTSD symptoms would be associated with
increased risk of incident VTE. Models adjusted for a range of
covariates determined from previous research,19,20 including
demographic factors, VTE-relevant medical risk factors,
medications, and adult health conditions and behaviors.
Although some of these covariates are likely confounders
(eg, socioeconomic status, parity) of the associations of
interest, others could lie on the pathway between trauma/
PTSD symptoms and VTE (eg, adult body mass index,
cigarette smoking).
Methods
Sample
The NHS II sample comprises 116 430 US female registered
nurses who were enrolled in 1989 when they were 25 to
42 years of age and followed with biennial questionnaires.
Women who reported a history of VTE (“DVT/PE”) at baseline
in 1989 were excluded to examine incident VTE. In 2008, a
subset of 60 804 women (aged 44–62 years) were sent a
supplemental questionnaire querying trauma exposure and
PTSD symptoms,21 and 54 224 women returned the ques-
tionnaire (89% response rate). The sample is predominantly
white (94%), and most women (78%) were married at baseline.
This study was approved by the Partners Healthcare Human
Research Committee. Returning questionnaires via mail
represented implied consent.
Trauma and PTSD Symptom Assessment
Lifetime exposure to 15 traumatic events (eg, physical
assault, sudden death of a loved one), in addition to “a
seriously traumatic event not already covered,” was assessed
with a modified version of the Brief Trauma Question-
naire.21,22 The Brief Trauma Questionnaire is considered a
reliable and valid measure of trauma exposure that parallels
interview measures of trauma exposure.21–23 Kappa coeffi-
cients for the presence of trauma have been found to range
from 0.60 to 1.00, with most kappas above 0.74.23 Women
reported which event occurred first (if reporting multiple
events) and which was their worst experience, along with their
ages at the first and worst events. Women also reported
whether they ever experienced PTSD symptoms in relation to
their worst trauma. Seven PTSD symptoms occurring subse-
quent to the worst trauma were queried using the Short
Screening Scale for Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) PTSD.24 The trauma
exposure and PTSD symptom data were used to derive
information on PTSD symptom severity and age of onset.
Self-reported age of PTSD symptom onset has had excellent
test–retest reliability in this sample (intraclass correlation
coefficient=0.95 based on comparisons of reported age of
PTSD symptom onset on the questionnaire and reported age
of onset in a subset of women who completed a “gold
standard” highly structured diagnostic interview for PTSD25).
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For each year of the study, participants were classified into
5 groups according to dates of trauma exposure and severity
of PTSD symptoms: (1) no trauma exposure, (2) trauma-
exposed and reported no PTSD symptoms, (3) trauma-
exposed and reported 1 to 3 symptoms, (4) trauma-exposed
and reported 4 to 5 symptoms, and (5) trauma-exposed and
reported 6 to 7 symptoms. Women who reported never having
experienced trauma were classified as having no trauma
exposure. PTSD symptoms were only assessed in relation to
women’s self-defined worst trauma. Therefore, age of PTSD
symptom onset was established according to the age of worst
trauma. Thus, following their first trauma, women were
categorized as being trauma-exposed with no PTSD symp-
toms. After their worst trauma, women were categorized as
having the number of PTSD symptoms reported with respect
to the worst event. If women reported only 1 trauma, the
dates of the first and worst traumas were the same. The
trauma/PTSD symptom groups were based on previous
research with the Short Screening Scale for DSM-IV PTSD
recommending scores of 4+24 and 6+26 as clinical cutoffs for
PTSD. Thus, we had 1 group of women with trauma and
subclinical PTSD symptoms and 2 groups of women with
trauma and PTSD symptom numbers above the recommended
clinical cutoff on this screening questionnaire, with the latter
2 grouped with respect to increasing symptom severity.
Furthermore, whereas most research on PTSD and chronic
disease has often conflated trauma and PTSD symptoms, we
were able to examine VTE onset in women with no trauma
exposure, trauma exposure and no symptoms, and trauma
exposure and varying symptom severity.
VTE Assessment
At each biennial follow-up, women reported whether they had
a physician-diagnosed VTE (“DVT/PE”) in the past 2 years. In
the current study, we considered cases of incident VTE as
reported on the 1991–2011 questionnaires (n=960). As in
prior research in the NHS II using self-reported medical
conditions,27,28 we used the date of the first questionnaire on
which VTE was reported for time to event. The severity of
diagnosis, in conjunction with the extensive treatment and
therapeutic monitoring and follow-up that patients with VTE
undergo, make it likely that VTE events are reported with high
accuracy, particularly in this cohort of nurses with high health
literacy. Validation of DVT and review of medical records for
PE cases in the NHS II supports that nurse VTE reports are
highly accurate when compared to medical record review.20,29
In a validation study of 101 self-reported cases of DVT for
which medical records were available, 95 (94%) cases were
confirmed, 2 (2%) cases were probable, and only 4 (4%) cases
were not confirmed.29 Additionally, per protocols in the NHS II
cohort, medical records are routinely requested from nurses
who have no history of malignancy and who report a PE;
record review for this subset of cases is conducted by
physicians blind to the trauma/PTSD symptom primary
exposure. Imaging was considered diagnostic of PE if a
ventilation/perfusion lung scan was read by a radiologist as
high probability for PE, or if there was a filling defect on
contrast-enhanced computed tomography scan of the pul-
monary vasculature or on catheter-based pulmonary angiog-
raphy. Idiopathic PE, the focus for the current study, was
defined by the absence of recent surgery, major physical
trauma (eg, fracture), or active malignancy in the medical
record. Cases confirmed by record review were considered
“definite cases.” We classified PE events as “probable cases”
if a participant or relative verbally confirmed the report when
it was followed up but access to medical records was denied
or unable to be attained.14 We considered the subset of
probable and definite idiopathic PE cases (n=157) as our
outcome in a sensitivity analysis.
Covariates
The following demographics and early childhood factors were
examined as potential confounders: age, race/ethnicity
(African American, Latina, Asian, white, other), maximum
parental education at the participant’s birth (high school or
less, some college, 4+ years of college), parental history ofMI,30
and somatotype at age 5 (to estimate childhood adiposity).
Consistent with prior research in the NHS cohorts,19,31
time-varying indicators for VTE-relevant medical risk factors,
medications, and adult health behaviors and conditions were
also included as covariates. Parity (nulliparous, 1, 2–3, 4+
children), oral contraceptive use (never used, current user,
former user; oral contraceptives were predominantly estrogen
and progesterone-containing: less than 2.26% of women used
progestin-only oral contraceptives), and menopausal status
and HT use (premenopausal, postmenopausal/never HT,
postmenopausal/past HT, postmenopausal/current HT, post-
menopausal/missing HT, unknown menopausal status) were
assessed biennially. Current nonaspirin nonsteroidal anti-
inflammatory drug use (yes/no) was assessed with each
biennial questionnaire except for the 1991 assessment.
Physician-diagnosed hypertension, hypercholesterolemia,
coronary heart disease (MI or angina), cancer (excluding
nonmelanoma skin cancer), type 2 diabetes mellitus, and
rheumatologic disease (rheumatoid arthritis or systemic lupus
erythematosus) were also reported at each biennial assess-
ment with the exception of rheumatologic disease, which was
not queried on the 1989 or 1995 questionnaires. Adult health
behaviors were assessed at baseline via self-report and
updated biennially, unless otherwise noted. Adult body mass
index in kg/m2 was computed from self-reported height and
weight (validated in prior NHS research32), and categorized as
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<22.5, 22.5 to <25, 25 to <27.5, 27.5 to <30, 30 to <35, and
35+.19 Women were classified as nonsmokers, former
smokers, or current smokers of 1 to 14, 15 to 24, or
25+ cigarettes/day. Alcohol consumption (0, 1–<5, 5–<10,
10–<20, or 20+ g/day) was assessed in 1989, 1991, 1995,
1999, 2003, and 2007. Physical activity (<3, 3–<9, 9–<18,
18–<27, or 27+ metabolic equivalent hours/week) was
measured in 1989, 1991, 1997, 2001, 2005, and 2009. Diet
was assessed every 4 years beginning in 1991. Diet quality
was quantified based on the Alternative Healthy Eating
Index33 and divided into quintiles, with the highest quintile
representing the healthiest diet. Antidepressant use is
frequently prescribed for PTSD34 and is associated with
increased risk for VTE.35 Lifetime antidepressant use was
assessed in 1993, and regular past 2-year antidepressant use
was assessed in 1997, 2001, 2003, 2005, and 2007. Women
who endorsed lifetime antidepressant use in 1993 were
coded as having used antidepressants from 1989 to 1993;
use was updated as available.
The following variables were used in sensitivity analyses
adjusting for type of worst traumatic event, depression, and
engagement with the medical system, respectively. We
classified women’s worst traumatic events (ie, the traumas
to which PTSD symptoms were anchored) as (1) interpersonal
violence (childhood physical abuse, physical assault,
unwanted sexual contact), (2) other traumatic event to self
(eg, car accident, natural disaster exposure), or (3) traumatic
event occurring to others (eg, sudden death of a loved one,
witnessing violence). Lifetime depression history (experienc-
ing depressive symptoms for 2+ weeks) was first assessed in
2001, and women reported whether they experienced
depressive symptoms for 2+ weeks or received a diagnosis
of depression in the past 2 years at the 2003, 2005, 2007,
and 2009 biennial assessments. Women who endorsed
lifetime depression in 2001 were coded as having depression
from 1989 to 2001, and depression history was updated as
available based on the 2003, 2005, 2007, and 2009
questionnaires. Women also reported whether they had a
physical exam in the past 2 years on the 1989, 2001, 2003,
2005, 2007, and 2009 biennial questionnaires. Women who
reported a physical exam in 1989 were coded as having had a
physical from 1989 to 1999; physical exam status was
updated as available.
Exclusions
A flowchart of exclusions for deriving the analytic sample
(n=49 296) is shown in Figure. Compared to women in the
analytic sample, participants who provided trauma/PTSD
symptom data but who were excluded from analyses were
similar on demographics, family history, and childhood
adiposity. Cumulative VTE incidence rates from 1989 to
2011 were comparable for those included (1.9%) and
excluded (2.1%), as well as for those who did (2.0%) and did
not (1.8%) receive the trauma and PTSD screening supple-
mental questionnaire.
Statistical Analysis
We investigated whether trauma exposure and PTSD symp-
toms were associated with incident VTE with Cox proportional
hazards models to calculate hazard ratios (HRs) and 95% CIs.
Participants contributed person-time from baseline in 1989
until VTE onset, death, the end of follow-up in 2011, or their
last returned questionnaire (ie, if they did not remain in the
study to complete the 2011 assessment).
We tested a series of increasingly adjusted models. Model
1 adjusted for age. Model 2 adjusted for true potential
confounders including demographics, family history, and
childhood adiposity. Model 3 adjusted for VTE-relevant
medical risk factors, medications, and adult health behaviors
and conditions. These covariates included parity, oral
contraceptive use, nonaspirin nonsteroidal anti-inflammatory
drug use, menopausal status and HT use, antidepressant use,
hypertension, hypercholesterolemia, coronary heart disease,
cancer, type 2 diabetes mellitus, rheumatologic disease, body
mass index, physical activity, diet quality, cigarette smoking,
and alcohol consumption. Missing data in covariates were
handled by treating missing as a separate category. Variables
added in Model 3 were time-varying covariates and were
updated every 2, 4, or 6 years as available. Models were
lagged such that for each period of prediction (eg, VTE status
on the 1995 questionnaire), covariates added in Model 3
were lagged by 1 period (eg, data from the 1993 question-
naire) and trauma/PTSD symptom status was lagged to
represent the year prior to the period for these covariates
(eg, trauma/PTSD symptoms in 1992). We lagged models in
this way to reduce the likelihood of prodromal disease
influencing PTSD symptoms and the health behaviors and
conditions assessed close in time to PTSD symptoms yet
preceding VTE.
We conducted 5 sensitivity analyses. First, given the broad
range of trauma exposure in our sample and the fact that
conditional probability of developing PTSD varies for different
traumas (eg, interpersonal violence has a higher conditional
probability of PTSD compared to natural disaster exposure),11
we re-estimated Model 2 adjusting for worst trauma type
(interpersonal violence, other traumatic event to self, trau-
matic event occurring to others; women not exposed to
trauma were coded as “none” and were included as the
reference group) as a categorical covariate. Second, we
examined the association between trauma/PTSD symptom
status with incidence of the subset of 157 PE events
confirmed by additional information or record review over
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the 22-year study period. Third, given that depression is
often comorbid with PTSD and has been associated with VTE
risk,9,10 we re-estimated Model 2 adjusting for lifetime
history of depression. Fourth, we addressed possible ascer-
tainment bias (ie, that women with PTSD symptoms might be
more likely to present to treatment providers with symptoms
that would also prompt assessment for VTE) by covarying
whether nurses had physical exams in addition to Model 2
covariates as a way to account for engagement with the
medical system. Fifth, we considered the potential for recall
bias by analyzing prospectively only new-onset VTE events
reported after assessment of trauma/PTSD symptoms
(2008) on the 2009 and 2011 questionnaires (n=48 525;
189 new VTE events).
Results
Table 1 presents participant characteristics by trauma expo-
sure and PTSD symptoms at baseline. Over two thirds of women
(69%, n=34 118) reported being exposed to a traumatic event
by the 1989 baseline assessment. Of those reporting trauma
exposure at baseline, most (72%; n=24 714) reported no PTSD
symptoms, 14% reported 1 to 3 symptoms (n=4706), 8%
reported 4 to 5 symptoms (n=2817), and 6% reported 6 to 7
symptoms (n=1881). Over the course of the study period, an
additional 5326 women reported trauma exposure.
There were 960 self-reported VTE events over the 22-year
follow-up. Compared to no trauma exposure, trauma alone and
trauma with PTSD symptoms were each associated with
Trauma-exposed but did 
not report age at worst 
trauma (n=2,772)
Missing responses on 
the PTSD questionnaire 
(n=1,032)
Further exclusions for:
116,430 enrolled in NHS II cohort in 1989
55,626 participants were not mailed the 
PTSD questionnaire
60,804 participants were mailed the PTSD 
questionnaire
6,580 participants did not return 
the PTSD questionnaire
54,224 participants returned the 
PTSD questionnaire
Reporting VTE at or 
before baseline in 1989 
(n=1,124)
Final analytic sample:
49,296
Figure. Exclusions for deriving the analytic sample. NHS II indicates Nurses’ Health Study II; PTSD,
posttraumatic stress disorder; VTE, venous thromboembolism.
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Table 1. Baseline Participant Characteristics as a Function of Trauma Exposure and PTSD Symptoms at the NHS II 1989
Assessment (N=49 296)
No Trauma
(n=15 178)
Trauma-Exposed (n=34 118)
No Symptoms
(n=24 714)
1 to 3 Symptoms
(n=4706)
4 to 5 Symptoms
(n=2817)
6 to 7 Symptoms
(n=1881)
Mean (SD)
or % (n)
Mean (SD)
or % (n)
Mean (SD)
or % (n)
Mean (SD)
or % (n)
Mean (SD)
or % (n)
Age, y 34 (5) 35 (5) 35 (4) 35 (4) 35 (4)
Parents’ education at birth, ≥college, % 23.6 (3584) 22.3 (5503) 22.6 (1065) 22.2 (625) 24.9 (468)
Parental history of myocardial infarction, % 33.6 (5097) 37.0 (9137) 37.6 (1771) 39.7 (1118) 37.2 (699)
Highest somatotype, age 5, % 6.2 (939) 7.0 (1722) 6.8 (318) 7.6 (214) 8.4 (158)
White race, % 93.5 (14 186) 93.8 (23 179) 94.2 (4431) 94.7 (2668) 94.6 (1779)
Parity, %
Nulliparous 33.1 (5029) 26.3 (6491) 25.9 (1221) 26.4 (745) 30.2 (568)
1 child 17.5 (2650) 18.7 (4614) 18.3 (862) 19.9 (561) 19.8 (372)
2 to 3 children 46.5 (7056) 50.4 (12 455) 50.4 (2373) 48.3 (1361) 44.6 (838)
4+ children 2.9 (443) 4.7 (1154) 5.3 (250) 5.3 (150) 5.5 (103)
Oral contraceptive use, %
Never 18.7 (2845) 15.3 (3771) 14.2 (667) 13.2 (373) 13.1 (246)
Former user 66.0 (10 021) 73.1 (18 059) 75.2 (3541) 76.6 (2159) 77.5 (1458)
Current user 15.1 (2295) 11.6 (2860) 10.5 (493) 10.0 (281) 9.4 (177)
Premenopausal status, % 97.8 (14 837) 97.1 (23 997) 96.8 (4555) 96.0 (2705) 95.3 (1792)
Nonaspirin nonsteroidal anti-inflammatory
drug user, %
16.1 (2443) 19.2 (4742) 20.2 (950) 23.7 (668) 27.0 (507)
Hypercholesterolemia, % 9.4 (1419) 10.7 (2640) 10.5 (494) 13.0 (365) 13.2 (249)
Hypertension, % 4.1 (618) 5.1 (1259) 5.8 (271) 7.2 (202) 6.9 (129)
Coronary heart disease, %* 0.1 (22) 0.3 (67) 0.7 (33) 1.0 (27) 1.0 (19)
Cancer, %† 0.5 (81) 1.0 (244) 1.1 (51) 1.0 (27) 1.1 (21)
Type 2 diabetes mellitus, % 0.5 (75) 0.7 (168) 0.6 (26) 0.7 (19) 0.9 (17)
Rheumatologic disease, %‡ 0.5 (73) 0.8 (202) 1.1 (53) 1.3 (37) 1.4 (26)
Body mass index, kg/m2 23.5 (4.6) 23.9 (4.8) 24.0 (4.9) 24.2 (5.1) 24.2 (5.3)
Cigarette smoking, %
Never 72.3 (10 978) 65.9 (16 297) 62.3 (2933) 60.8 (1712) 55.7 (1047)
Former smoker 18.2 (2755) 22.3 (5518) 24.8 (1167) 26.8 (756) 27.6 (519)
Current smoker 9.2 (1399) 11.4 (2821) 12.5 (587) 11.9 (335) 16.4 (308)
Alcohol intake, g/day 2.9 (5.0) 3.0 (5.6) 3.2 (6.0) 2.9 (5.5) 3.1 (6.0)
Physical activity, MET h/week§ 24.2 (35.7) 24.7 (35.9) 23.4 (33.2) 24.0 (34.3) 24.3 (31.4)
Worst diet (1st quintile) on the alternative
healthy eating index, %k
20.3 (3074) 18.1 (4481) 16.8 (791) 16.8 (472) 15.3 (288)
Antidepressant use, %¶ 6.4 (970) 10.2 (2533) 13.9 (655) 22.1 (622) 32.7 (616)
NHS II indicates Nurses’ Health Study II; PTSD, posttraumatic stress disorder.
*Myocardial infarction or angina.
†Excluding nonmelanoma skin cancer.
‡Rheumatoid arthritis or systemic lupus erythematosus.
§MET hours/week=metabolic equivalent hours/week.
kFirst assessed in 1991.
¶First assessed in 1993.
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heightened risk of VTE, with the greatest elevation in risk
observed with the highest PTSD symptom levels (Table 2). For
example, the risk of VTE was 2.42-fold higher among women
with trauma/6 to 7 symptoms than in women with no trauma
exposure after adjusting for demographics, family history, and
childhood adiposity (Table 2, Model 2). Most trauma and PTSD
symptom groups demonstrated statistically significantly ele-
vated risk in the fully adjusted model (excepting trauma/1–3
symptoms), despite attenuation in the HRs (Table 2, Model 3).
To address whether the type of worst traumatic event
accounted for associations between PTSD symptoms and
incident VTE, we included worst trauma type as a categorical
covariate along with Model 2 covariates. Although the HRs
were attenuated in this model, all the trauma/PTSD symptom
groups were significantly associated with increased risk of
developing VTE except for the trauma/1 to 3 symptoms group
(notably, this group was not characterized by significantly
elevated risk of incident VTE in the fully adjusted model):
trauma/no symptoms: HR=1.39 (95% CI, 1.03–1.87); trauma/
1 to 3 symptoms: HR=1.18 (95% CI, 0.84–1.65); trauma/4 to
5 symptoms: HR=1.66 (95% CI, 1.17–2.35); trauma/6 to 7
symptoms: HR=2.02 (95% CI, 1.40–2.91).
Risk estimates for trauma exposure and the highest level
of PTSD symptoms were also elevated when we restricted
analyses to the 157 probable and definite cases of idiopathic
PE that were confirmed by additional information or record
review. However, in this sensitivity analysis, HRs in the
minimally adjusted model were substantially attenuated and
not statistically significant, and confidence intervals
were wide (trauma/no symptoms: HR=1.26 [95% CI, 0.84–
1.91]; trauma/1–3 symptoms: HR=1.14 [95% CI, 0.65–2.00];
trauma/4–5 symptoms: HR=0.87 [95% CI, 0.42–1.78];
trauma/6–7 symptoms: HR=1.53 [95% CI, 0.77–3.05]).
When covarying lifetime depression along with Model 2
covariates, all trauma and PTSD symptom groups remained
significantly associated with increased VTE risk, although
HRs were attenuated, especially for those with more
PTSD symptoms (trauma/no symptoms: HR=1.68 [95% CI,
1.39–2.02]; trauma/1–3 symptoms: HR=1.34 [95% CI, 1.05–
1.72]; trauma/4–5 symptoms: HR=1.77 [95% CI, 1.36–2.29];
trauma/6–7 symptoms: HR=2.06 [95% CI, 1.55–2.74]).
Trauma exposure and PTSD symptoms continued to be
characterized by heightened risk for developing first VTE
during follow-up when we accounted for physical exam
attendance in addition to Model 2 covariates (trauma/no
symptoms: HR=1.72 [95% CI, 1.42–2.06]; trauma/1–3 symp-
toms: HR=1.43 [95% CI, 1.12–1.83]; trauma/4–5 symptoms:
HR=1.99 [95% CI, 1.54–2.57]; trauma/6–7 symptoms:
HR=2.38 [95% CI, 1.80–3.15]).
In the analysis of 189 prospectively detected new-onset
VTE events, trauma exposure and PTSD symptoms were
associated with nominally increased risk of incident VTE
compared to no trauma exposure when adjusting for Model 2
covariates (trauma/no symptoms: HR=1.55 [95% CI, 1.01–
2.38]; trauma/1–3 symptoms: HR=1.55 [95% CI, 0.93–2.57];
trauma/4–5 symptoms: HR=1.22 [95% CI, 0.66–2.25];
trauma/6–7 symptoms: HR=1.82 [95% CI, 0.96–3.43]).
However, aside from the HR for trauma/no symptoms, results
did not reach statistical significance when analyses were
restricted to the smaller number of cases reported in this brief
follow-up period.
Discussion
This is the first study to demonstrate that trauma and PTSD
symptoms are associated with increased risk of incident VTE in
a large cohort of younger and middle-aged women over a 22-
year period. Trauma exposure and elevated PTSD symptoms
have been identified as risk factors for other cardiovascular
diseases in this cohort of women,14 and our work extends these
findings to the third most common cause of cardiovascular
death: VTE. Women with the highest PTSD symptom levels had
Table 2. Adjusted Hazard Ratios (95% CI) for the Association of Trauma Exposure and PTSD Symptoms With Risk of Incident
Venous Thromboembolism (960 Self-Reported Events), 1989–2011
No Trauma
Trauma-Exposed
No Symptoms 1 to 3 Symptoms 4 to 5 Symptoms 6 to 7 Symptoms
Cases, n (person-y) 144 (280 907) 520 (567 661) 117 (148 868) 102 (92 408) 77 (59 083)
Hazard Ratio (95% CI)
Model 1: Age-adjusted model 1 (ref) 1.73 (1.44–2.08) 1.44 (1.13–1.85) 2.04 (1.58–2.63) 2.44 (1.85–3.23)
Model 2: Minimally adjusted model* 1 (ref) 1.72 (1.43–2.08) 1.44 (1.12–1.84) 2.00 (1.55–2.59) 2.42 (1.83–3.20)
Model 3: Fully adjusted model† 1 (ref) 1.60 (1.33–1.93) 1.26 (0.98–1.62) 1.65 (1.27–2.15) 1.90 (1.43–2.54)
PTSD indicates posttraumatic stress disorder.
*Adjusted for age, race/ethnicity, parental education, parental history of myocardial infarction, and age 5 somatotype.
†Additionally adjusted for parity, oral contraceptive use, nonaspirin nonsteroidal anti-inflammatory drug use, menopausal status and hormone therapy use, antidepressant use,
hypercholesterolemia, hypertension, coronary heart disease (myocardial infarction or angina), cancer (excluding nonmelanoma skin cancer), type 2 diabetes mellitus, rheumatologic
disease (rheumatoid arthritis or systematic lupus erythematosus), body mass index, physical activity, diet quality, cigarette smoking, and alcohol consumption.
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the greatest elevation in risk of developing VTE, even when
adjusting for a variety of potential confounders and mediators
that were lagged to reflect women’s health status prior to VTE
onset. Women with trauma exposure who did not report PTSD
symptoms also exhibited increased risk of VTE incidence
compared to women with no trauma exposure, although the
magnitude of elevated risk was not as substantial as for women
with high PTSD symptom levels. Initial research has linked
psychosocial factors, including chronic stress36 and depres-
sion,9,10 to VTE risk. Our study further underscores the role that
psychosocial variables may play in contributing to the devel-
opment of VTE, and suggests that the experience of extremely
stressful, traumatic events and related posttraumatic stress
reactions may have even more widespread cardiotoxic effects
than has previously been considered.
VTE is characterized by high mortality rates and a high rate
of recurrence among survivors,2 and it has been identified as
an important health concern for women in particular.3
Furthermore, studying the link between PTSD symptoms
and VTE specifically in a sample of younger and middle-aged
women has particular relevance for understanding VTE risk in
women. Even though the overall rate of first VTE is similar in
men and women,4 incidence rates are higher in women of
childbearing age than in men of the same age.4,5 This
difference in incidence rate likely reflects, in part, VTE due to
pregnancy and/or oral contraceptive use during childbearing
years. However, roughly a quarter to a half of VTE cases,
overall, are classified as occurring in the absence of major
established risk factors,6 thus emphasizing the need for
greater understanding of susceptibility to VTE. PTSD is twice
as common in women as in men,11 and our findings suggest
that elevated PTSD symptoms (over and above the effects of
trauma type and depression, a psychological disorder that is
frequently comorbid with PTSD and has also been linked with
risk of VTE9,10) may be an important vulnerability factor for
developing VTE in women. Given that VTE is a leading cause of
mortality among pregnant and recently postpartum women,3
and in light of female-specific risk factors for VTE related to
reproductive hormone exposure,3 pregnant women with PTSD
symptoms or women with PTSD symptoms who are using
hormone therapy may represent especially vulnerable groups
with respect to VTE risk. Additional research in these
particular populations is needed, but our findings highlight
certain individuals who might benefit from close monitoring by
healthcare providers in order to prevent possible VTE.
Both biological and behavioral mechanisms likely underlie
the associations between trauma, PTSD symptoms, and VTE
risk. Acute (eg, mental stress) and chronic stress (eg, job strain,
low socioeconomic status) have been associated with a
hypercoagulable state as indicated by increased blood levels
of circulating procoagulant markers (eg, fibrinogen, clotting
factor VII) that are known to counteract anticoagulant
processes.37 Furthermore, there is cross-sectional evidence
suggesting that PTSD is characterized by elevated levels of
clotting markers.16 Hypercoagulable states may trigger VTE by
increasing the likelihood of clot formation, and longitudinal
research that examines the effects of trauma exposure and
PTSD on coagulation and fibrinolysis is needed. Increased
inflammation and endothelial damage—both of which have
been observed in those with elevated PTSD symptoms15,17—
are thought to heighten susceptibility to developing VTE as
well.7 Thus, several of the covariates included in the fully
adjusted model likely represent additional underlying pro-
cesses linking trauma/PTSD symptoms to VTE; this is consis-
tent with the attenuation in HRs in the fully adjusted model
relative to the minimally adjusted model. Elevated PTSD
symptoms are associated with increased risk for numerous
chronic medical conditions, including MI and stroke,14 type 2
diabetes mellitus,38 and rheumatologic disease,39 which in turn
have also been linked to VTE risk7,40 and could be markers for
underlying inflammation or hypercoagulability.
Trauma and PTSD symptoms have also been associated
with health risk behaviors that have been tied to increased
risk of developing VTE in women. For example, women with
elevated PTSD symptoms in the NHS II have been found to be
at increased risk of becoming overweight or obese over
time,41 and body mass index has been identified as a major
risk factor for PE in NHS participants.19 Furthermore,
compared to women with no history of trauma, women with
elevated PTSD symptoms in our sample were more likely to
smoke cigarettes and use antidepressants—2 behavioral
factors that have also been linked to vulnerability to
developing VTE.7,35 Although preliminary, findings from our
fully adjusted model highlight some candidate behavioral
mechanisms underlying associations between trauma, PTSD
symptoms, and incident VTE. Moreover, studying these
processes separately in women and in men holds promise
for best understanding underlying mechanisms of risk given
sex differences in health behaviors (eg, men are more likely to
smoke than women but women have been found to be less
likely to meet current aerobic physical activity guidelines than
men5). Ultimately, it is likely that trauma exposure and PTSD
symptoms are associated with various forms of dysregulation
at the biological and behavioral level that contribute to risk for
numerous chronic medical conditions, including VTE. Further
work is needed to delineate the relative contributions of
biological and behavioral factors that underlie the associa-
tions between trauma exposure, PTSD symptoms, and VTE
onset in women. Such work has the potential to not only
further understanding of mechanistic processes but also
identify more specific targets for prevention and intervention.
These novel findings contribute importantly to a growing
literature suggesting that trauma and PTSD symptoms may
truly inflict cardiovascular damage, harming health beyond the
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significant mental health burden imposed. However, several
limitations are worth noting. Trauma and PTSD symptoms were
assessed retrospectively, although the reliability of dating of
PTSD symptom onset has previously been demonstrated in this
sample.25 Additionally, because PTSD symptoms were
assessed with a screening measure, some misclassification is
possible, and further research with more comprehensive
diagnostic interviews may not only add more precision but
also address the extent to which diagnoses of PTSD are related
to VTE. Furthermore, we assessed PTSD symptoms based on
DSM-IV PTSD criteria. Even though most of the DSM-5 and
DSM-IV PTSD criteria are highly similar, research using DSM-5
PTSD criteria is needed. Other limitations are that our primary
outcome comprised VTE events based on self-report, and we
lacked information on the exact date of VTE (as in prior NHS II
research with self-reported outcomes,27,28 we used the date of
the first questionnaire on which VTE was reported for time to
event). However, being nurses, NHS II participants have high
health literacy, and reporting of VTE events has been validated
in this cohort.29 Furthermore, when we restricted analyses to
the small subset of PE events confirmed by additional
information or record review, although not statistically signif-
icant, effect sizes were consistent with the notion that trauma
exposure and elevated PTSD symptoms are associated with
increased VTE risk. In fact, the PE cases considered here likely
represent only a subset of possible VTE events since medical
records were requested for PE events solely in women without
a history of malignancy. Although additional research with
confirmed PE and DVT cases would be useful, we suspect
results would be similar.
We also lacked information on several established VTE risk
factors, including thrombophilia and genetic risk for clotting
disorders. Furthermore, even though warfarin/Coumadin use is
unlikely to confound associations between trauma, PTSD
symptoms, and VTE, we were not able to adjust sufficiently for
these medications due to limited information in the NHS II. In
addition, women needed to remain in the study until 2008 in
order to provide data on trauma and PTSD symptoms, and
survivor bias is thus a possible concern. However, study
retention is high (>90%biennial response rate), and themortality
rate is low (only 1.6% of the NHS II cohort was deceased by
2008). Finally, because the NHS II sample was representative of
the nursing profession at the time of recruitment in 1989, the
cohort is predominantly white and highly educated.
Despite these limitations, the current study has several
important and unique strengths. The NHS II cohort is a large
sample of civilian women exposed to a wide range of
traumatic experiences. The sample is richly characterized with
respect to risk for chronic disease, and the women have
repeatedly provided information on health behaviors, medi-
cation use, and medical conditions for over 20 years. Thus,
not only is this the first study to our knowledge to investigate
associations between trauma exposure, PTSD symptoms, and
incident VTE specifically in women, but the unique character-
istics of the NHS II cohort facilitate a highly detailed
examination of these issues, going beyond tests of the
primary association to take account of a broad array of
potential confounders and speculating possible underlying
mechanisms, as well as considering effects of trauma and
PTSD symptoms separately from one another.
Conclusions
Within the past decade, the National Institutes of Health,
Center for Disease Control, and Surgeon General have made
concerted efforts directed at VTE prevention.2 Given that VTE
is associated with long-term complications and high mortality
rates, it is critical to diagnose cases early and accurately.
However, this effort is frequently complicated by lack of VTE
awareness on the part of patients and healthcare providers
and by the often-silent presentation of VTE.2 Our findings
indicate that women with trauma exposure and elevated PTSD
symptoms may be especially susceptible to developing VTE
compared to women without trauma exposure. A growing
body of evidence consistently suggests that elevated PTSD
symptoms are a risk factor for cardiovascular diseases such
as MI and stroke,14 and our results suggest that PTSD
symptoms are associated with even more widespread
cardiovascular effects than perhaps initially recognized.
Screening for VTE risk in women with trauma and PTSD
symptoms may help to offset this vulnerability and reduce the
disease burden of VTE in women. Additional research is
needed to ascertain whether women with trauma exposure
and PTSD symptoms may particularly benefit from VTE
prevention measures, including weight loss and smoking
cessation. Ultimately, it is critical to test whether mitigating
symptoms of PTSD and trauma-related distress can offset the
risk of developing VTE in these vulnerable individuals.
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